ScreenerHero

BINV BioInvent International AB

STO · SE · Healthcare · Biotechnology · bioinvent.com
23.05SEK+0.66%Mkt Cap: 144.14M $P/E: —

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap144.14M USD
Enterprise Value113.59M USD
Revenue (TTM)3.11M USD
Gross Profit3.11M USD
Net Income (TTM)-31.84M USD
Revenue/Share0.49 SEK
Last Price23.05 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees108
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0015244520
Valuation
P/E (Trailing)—
P/E (Forward)-5.83
PEG0.27
EV/EBITDA-2.38
EV/Revenue36.53
P/S46.35
P/B4.75
EPS (TTM)-7.55
EPS (Forward)-3.93
52W Range
20.8016% of range34.85
52W High34.85 SEK
52W Low20.80 SEK
Profitability
Gross Margin100.00%
Oper. Margin-980.60%
EBITDA Margin0.00%
Profit Margin-146.96%
ROE-59.69%
ROA-49.59%
Growth
Revenue Growth-93.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.70M USD
CapEx (TTM)694.43K USD
FCF Margin-828.15%
FCF Yield-17.87%
Net Debt-30.55M USD
Net Debt/EBITDA0.64
Balance Sheet
Debt/Equity0.02
Current Ratio4.06
Quick Ratio3.95
Book Value/Sh4.82 SEK
Cash/Share5.18 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateDec 14, 2020
Analyst Consensus
Rating—
Target (Mean)84.92 SEK
Upside (mean)+268.4%
Target Range65.00 SEK – 110.00 SEK
65.00+268.4% to mean110.00
# Analysts4
Ownership
Shares Out.65.80M
Float31.44M
Insiders10.17%
Institutions57.82%
Technical
SMA 5023.11 (-0.3%)
SMA 20024.73 (-6.8%)
Beta0.02
S&P 52W Chg14.58%
Avg Vol (30d)87.11K
Avg Vol (10d)74.75K
Technical Indicators
RSI (14)51.3
MACD-0.1846
MACD Signal-0.2783
MACD Hist.+0.0937
BB Upper23.80 SEK
BB Middle22.56 SEK
BB Lower21.32 SEK
BB Width10.99%
ATR (14)0.8940 SEK
Vol Ratio (20d)0.77x